PwPepwise

GHK-Cu

Healing & Recovery

a.k.a. Copper Peptide GHK

Copper-binding tripeptide

GHK-Cu is a naturally occurring copper-binding tripeptide (glycyl-L-histidyl-L-lysine complexed with copper) found in human plasma, saliva, and urine.

§Dosing at a glance

4 protocols · from the research
What it's forDoseHow oftenHowFor how long
into the nose (Cognitive/Neurological — Animal)15 mg/kg——3 mos
Intraperitoneal (Pulmonary Fibrosis — Animal)20 μg——21 days
Intraperitoneal (Skeletal Muscle — Animal)0.2 mg/kg———
Intra-articular (Ligament Healing — Animal)0.3 mg/kgOnce weeklyTopicalApplied on the skin.4 wks

Approximate values pulled from the research — double-check before dosing.

§01Summary

GHK-Cu is a naturally occurring copper-binding tripeptide (glycyl-L-histidyl-L-lysine complexed with copper) found in human plasma, saliva, and urine. It plays a central role in tissue repair and regeneration, and its circulating levels decline with age — a pattern observed in conditions such as COPD, where lower plasma GHK correlates with reduced muscle mass19. In skin, GHK-Cu may stimulate collagen, elastin, and glycosaminoglycan synthesis3,11,14, and has been reported to modulate matrix metalloproteinase activity in ways that support balanced tissue remodeling8. Early human studies suggest it may improve subjective skin quality and support wound healing2, and a Phase 2 randomized clinical trial investigating its ability to accelerate wound re-epithelialization is currently underway1. Beyond skin, animal research has explored GHK-Cu across a broad range of applications: it has been reported to reduce lung inflammation and fibrosis in preclinical models9,10, attenuate features of Alzheimer's disease in transgenic mice12, improve cognitive function in aged animals5,7, and extend lifespan in C. elegans through mitochondrial and longevity pathway activation6. Human efficacy data across these emerging indications is actively developing, with the strongest current evidence concentrated in dermatological and wound-healing applications.

This is the layperson summary. Mechanism, dosing, the evidence base, and the published literature are in the sections below — every claim links to its source.

§02In depth

GHK-Cu (glycyl-L-histidyl-L-lysine copper(II) complex) is a tripeptide-metal chelate in which the histidyl imidazole and lysyl amine groups coordinate with a Cu²⁺ ion to form a stable square-planar complex. This configuration confers biological activity distinct from either the free peptide or free copper ion — although MMP-2 stimulatory effects in fibroblast cultures have been partially attributed to the copper moiety alone8, suggesting context-dependent contributions from each component.

At the extracellular matrix level, GHK-Cu upregulates transcription of Type I and Type III collagen mRNAs and stimulates net collagen synthesis at approximately twice the rate of non-collagen protein synthesis3. It also stimulates sulfated glycosaminoglycan synthesis in a biphasic, hormetic dose-response manner, with peak efficacy at 10⁻⁹ to 10⁻⁸ M and diminishing returns above this range11. Preferential stimulation of dermatan sulfate (extracellular) and heparan sulfate (cell-associated) — without effect on hyaluronic acid — suggests receptor-mediated or pathway-selective mechanisms rather than generalized cellular activation11. Simultaneous upregulation of MMP-2, TIMP-1, and TIMP-2 supports a model of coordinated, balanced matrix remodeling rather than net proteolysis8.

At the intracellular signaling level, GHK-Cu engages multiple converging pathways. It activates SIRT1, which in turn suppresses FoxO3a-mediated protein degradation, upregulates Nrf2-mediated antioxidant gene expression, and promotes PGC-1α-dependent mitochondrial biogenesis19. Molecular docking analysis suggests direct GHK-Cu binding to SIRT1 (binding energy −6.1 kcal/mol)19. In inflammatory contexts, GHK-Cu suppresses NF-κB p65 and p38 MAPK signaling, reducing TNF-α and IL-6 production9,10, and inhibits TGFβ1/Smad2/3 signaling to attenuate fibrotic processes9. In intestinal epithelial contexts, GHK-Cu upregulates SIRT1 while modulating STAT3 phosphorylation to promote tight junction protein expression (ZO-1, Occludin)13.

In C. elegans, GHK-Cu preserves mitochondrial membrane potential, shifts the balance from fission to fusion by regulating drp-1 and fzo-1, increases ATP biosynthesis, and transcriptionally activates the DAF-16 (FOXO ortholog) and SKN-1 (NRF2 ortholog) longevity pathways, upregulating downstream targets sod-3, gst-4, gcs-1, lys-7, and lys-86. In mammalian brain models, intranasal delivery reduces amyloid plaque burden, decreases MCP-1-mediated neuroinflammation, and reduces GFAP while increasing synaptophysin12, with route- and sex-dependent differences in transcriptomic signatures involving OXPHOS, MYC targets, and PI3K-AKT-mTOR pathways5,7. Pharmacokinetic characterization in humans is actively being studied; intact-skin transdermal permeation is negligible without enhancement strategies, and microneedle pretreatment enables meaningful dermal delivery with differential permeation kinetics between the peptide and copper moieties17.

§04Evidence & efficacy

Evidence base
141Studies
38Human
19Animal

GHK-Cu has demonstrated the most consistent evidence in dermatological and wound-healing contexts. In cultured fibroblasts, it has been shown to stimulate collagen (Type I and III), elastin, and glycosaminoglycan synthesis3,11,14, upregulate MMP-2 alongside balanced TIMP-1 and TIMP-2 expression8, and enhance proliferation and angiogenic growth factor production (bFGF, VEGF) in both normal and radiation-damaged fibroblasts16. In a rat wound chamber model, GHK-Cu produced concentration-dependent increases in collagen and total ECM accumulation through a TGF-beta-independent mechanism3. In the only published human RCT, objective measures of erythema resolution, wrinkle improvement, and skin quality following CO2 laser resurfacing did not significantly differ between GHK-Cu and vehicle groups, though patient-reported satisfaction scores were significantly higher in the GHK-Cu group (P=0.04)2. A Phase 2 split-wound RCT examining re-epithelialization of acute skin wounds is currently underway1.

In pulmonary models, GHK-Cu may reduce bleomycin-induced lung fibrosis and inflammation through Nrf2 activation, NF-κB suppression, and TGFβ1/Smad2/3 inhibition9, and may attenuate LPS-induced acute lung injury through antioxidant and anti-inflammatory pathways10. In skeletal muscle, it may improve muscle mass and strength in cigarette smoke-exposed mice via a SIRT1-dependent mechanism, with plasma GHK levels positively correlating with pectoralis muscle area in COPD patients19. In neurological models, intranasal GHK-Cu may improve hippocampal-dependent learning and reduce markers of neuroinflammation in aged mice5,7,12. In C. elegans, GHK-Cu extends lifespan and improves stress resistance through coordinated mitochondrial and DAF-16/SKN-1 pathway activation6. In a murine colitis model, GHK-Cu may promote mucosal healing via SIRT1/STAT3 signaling and reduce pro-inflammatory cytokines13.

§05Safety

GHK-Cu has demonstrated a favorable tolerability profile across the contexts in which it has been studied. In human cell-based safety testing, GHK-Cu showed no cytotoxicity and did not significantly upregulate skin irritation biomarkers (IL-1α, IL-8, HSPA1A, FOSL1) at concentrations of 58 and 580 μM, contrasting with significant inflammatory biomarker upregulation observed with free copper compounds (CuCl2 and copper acetate) at the same concentrations18. This indicates that peptide chelation of copper substantially mitigates the irritancy potential of the copper ion. Microneedle-assisted transdermal delivery in cellular and porcine skin models produced no observable signs of local irritation17. In the only published human RCT with safety reporting, no adverse events were noted in subjects using topical GHK-Cu following CO2 laser resurfacing2. In animal studies, intraperitoneal administration across multiple dose levels (0.2–20 μg/g/day)9, intra-articular injections4, and intranasal delivery at 15 mg/kg5,7,12 were all reported as well-tolerated with no noted adverse events across the studies reviewed. No drug interactions have been described in the available literature.

§06History

GHK (glycyl-L-histidyl-L-lysine) was first isolated from human plasma albumin in the early 1970s by Loren Pickart, who identified it as a serum factor capable of stimulating hepatic tissue function in older animals — an early indication of its regenerative properties. Subsequent work established that GHK exists naturally as a copper(II) chelate, and that the copper-complexed form confers substantially greater biological activity. By the late 1980s and early 1990s, GHK-Cu had attracted significant research interest as a wound healing agent, with foundational animal studies demonstrating in vivo stimulation of connective tissue accumulation, collagen mRNA upregulation, and ECM remodeling in rat wound chamber models3. High-impact publications through the 1990s and 2000s established its effects on fibroblast proliferation16, glycosaminoglycan synthesis11, and MMP/TIMP regulation8, building a mechanistic rationale for topical cosmetic and wound healing applications. GHK-Cu became widely incorporated into cosmeceutical formulations targeting skin aging and repair during this period. Human clinical investigation has been more limited; a small RCT in post-laser resurfacing patients was published in 20062, with a more rigorous Phase 2 split-wound RCT currently registered and in progress1. The research landscape has expanded meaningfully since the 2010s, with preclinical investigation extending into pulmonary fibrosis9, acute lung injury10, neurodegeneration12, skeletal muscle wasting19, and aging biology in invertebrate models6, positioning GHK-Cu as an active subject of translational longevity and regenerative medicine research.

§07References